Centre de Recherche Epidémiologie et Statistique, INSERM U1153, Paris, France2Centre d'Épidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique des Hôpitaux de Paris, Paris, France3Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cit.
Centre for Statistics in Medicine, Oxford, United Kingdom.
JAMA. 2014 Aug 13;312(6):623-30. doi: 10.1001/jama.2014.8166.
A persistent dilemma when performing meta-analyses is whether all available trials should be included in the meta-analysis.
To compare treatment outcomes estimated by meta-analysis of all trials and several alternative analytic strategies: single most precise trial (ie, trial with the narrowest confidence interval), meta-analysis restricted to the 25% largest trials, limit meta-analysis (a meta-analysis model adjusted for small-study effect), and meta-analysis restricted to trials at low overall risk of bias.
One hundred sixty-three meta-analyses published between 2008 and 2010 in high-impact-factor journals and between 2011 and 2013 in the Cochrane Database of Systematic Reviews: 92 (705 randomized clinical trials [RCTs]) with subjective outcomes and 71 (535 RCTs) with objective outcomes.
For each meta-analysis, the difference in treatment outcomes between meta-analysis of all trials and each alternative strategy, expressed as a ratio of odds ratios (ROR), was assessed considering the dependency between strategies. A difference greater than 30% was considered substantial. RORs were combined by random-effects meta-analysis models to obtain an average difference across the sample. An ROR greater than 1 indicates larger treatment outcomes with meta-analysis of all trials. Subjective and objective outcomes were analyzed separately.
Treatment outcomes were larger in the meta-analysis of all trials than in the single most precise trial (combined ROR, 1.13 [95% CI, 1.07-1.19]) for subjective outcomes and 1.03 (95% CI, 1.01-1.05) for objective outcomes). The difference in treatment outcomes between these strategies was substantial in 47 of 92 (51%) meta-analyses of subjective outcomes (meta-analysis of all trials showing larger outcomes in 40/47) and in 28 of 71 (39%) meta-analyses of objective outcomes (meta-analysis of all trials showing larger outcomes in 21/28). The combined ROR for subjective and objective outcomes was, respectively, 1.08 (95% CI, 1.04-1.13) and 1.03 (95% CI, 1.00-1.06) when comparing meta-analysis of all trials and meta-analysis of the 25% largest trials, 1.17 (95% CI, 1.11-1.22) and 1.13 (95% CI, 0.82-1.55) when comparing meta-analysis of all trials and limit meta-analysis, and 0.94 (95% CI, 0.86-1.04) and 1.03 (95% CI, 1.00-1.06) when comparing meta-analysis of all trials and meta-analysis restricted to trials at low risk of bias.
Estimation of treatment outcomes in meta-analyses differs depending on the strategy used. This instability in findings can result in major alterations in the conclusions derived from the analysis and underlines the need for systematic sensitivity analyses.
在进行荟萃分析时,一个持久的难题是是否应将所有可用的试验都纳入荟萃分析。
比较荟萃分析中所有试验和几种替代分析策略的治疗结果:最精确的单个试验(即置信区间最窄的试验)、仅限于最大的 25%试验的荟萃分析、限制荟萃分析(一种调整了小研究效应的荟萃分析模型)和限制在整体低偏倚风险试验中的荟萃分析。
2008 年至 2010 年在高影响力期刊上发表的 163 项荟萃分析和 2011 年至 2013 年在 Cochrane 系统评价数据库中发表的 71 项荟萃分析:92 项(705 项随机临床试验[RCT])为主观结局,71 项(535 项 RCT)为客观结局。
对于每项荟萃分析,评估了荟萃分析中所有试验与每种替代策略之间治疗结果的差异,以比值比(ROR)表示,考虑了策略之间的依赖性。差异大于 30%被认为是显著的。通过随机效应荟萃分析模型对 ROR 进行组合,以获得样本的平均差异。ROR 大于 1 表示荟萃分析中所有试验的治疗效果更大。分别对主观和客观结果进行了分析。
与单个最精确的试验相比(合并 ROR,1.13[95%置信区间,1.07-1.19]),所有试验荟萃分析的治疗效果更大,主观结果(所有试验荟萃分析的结果显示出更大的效果在 47/92 项[51%]的荟萃分析中)和客观结果(所有试验荟萃分析的结果显示出更大的效果在 28/71 项[39%]的荟萃分析中)。在 47/92 项(51%)主观结局荟萃分析(荟萃分析中所有结局均显示更大结局的有 40/47 项)和 28/71 项(39%)客观结局荟萃分析(荟萃分析中所有结局均显示更大结局的有 21/28 项)中,这些策略之间的治疗效果差异显著。比较所有试验荟萃分析和 25%最大试验荟萃分析时,主观和客观结局的合并 ROR 分别为 1.08(95%CI,1.04-1.13)和 1.03(95%CI,1.00-1.06),比较所有试验荟萃分析和限制荟萃分析时,分别为 1.17(95%CI,1.11-1.22)和 1.13(95%CI,0.82-1.55),比较所有试验荟萃分析和低风险偏倚试验荟萃分析时,分别为 0.94(95%CI,0.86-1.04)和 1.03(95%CI,1.00-1.06)。
荟萃分析中治疗结果的估计取决于所使用的策略。这种发现的不稳定性可能导致分析得出的结论发生重大变化,并强调需要进行系统的敏感性分析。